Degenerative eye diseases are often related to major pathologies diagnosed in advanced stages and they can also result from an incomplete “integrated approach” to patients. They now represent a real health emergency, with high direct and indirect social costs.
In particular, Diabetic Macular Edema (EMD) is a disabling eye disease, caused by diabetes, which provokes a progressive vision decrease which can also lead to blindness.
Parameters such the definition of the best available treatment and the correct adherence to identified therapy, together with a structured assessment in the health-economics sector, must become the starting points of any future choice.
Thus, the Conference goal is to promote a fruitful debate between clinicians, patients, academics and institutional stakeholders to define new clinical and managment paths allowing access to the latest therapeutic solutions to all people with serious eye diseases, while guaranteeing system sustainability.